- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02603679
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (PREDIX LumB)
PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors With High Proliferation or Low Proliferation With Metastatic Nodes. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Study Overview
Status
Detailed Description
Patients are randomized to either weekly treatment with paclitaxel (arm A) or endocrine treatment in combination with palbociclib (arm B) for 12 weeks. Choice of endocrine treatment is for pre- and perimenopausal women and all men tamoxifen 20 mg daily, alternatively for women in this age cohort, an LHRH analogue in combination with an aromatase inhibitor, for all postmenopausal women treatment with an aromatase inhibitor. The aromatase inhibitors to be used according to local practice are anastrozole 1 mg daily, exemestane 25 mg daily, or letrozole 2.5 mg daily. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women). Postmenopausal women receive an aromatase inhibitor.
After 12 weeks, patients without signs of disease progression (PD) are switched to either endocrine treatment in combination with palbociclib (arm A) or weekly treatment with paclitaxel (arm B) for 12 weeks. Postoperatively, patients receive three 3-weekly courses of chemotherapy with a combination of epirubicin and cyclophosphamide.
Before start, after 6, 12, 18 and 24 weeks of treatment, radiological assessments of tumor size are performed using mammography and ultrasound alt. MRI breast; PET-CT, confined to the breast and regional lymph nodes, before start, after 12 and 24 weeks, blood tests before start, after 1 week, 12, 18 and 24 weeks. Physical examinations are performed before start and then four-weekly after weeks 4, 8, 12, 16, 20 and 24 weeks of treatment.
In case of disease progression during ongoing study treatment, individualized management in the patient's best interest must be considered, in which case surgery is the primary option.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 17176
- Karolinska University Hospital
-
Stockholm, Sweden, 11883
- Sodersjukhuset
-
Stockholm, Sweden
- Capio S:t Göran Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Female or male patients with breast cancer confirmed by histology
- Tumor and blood samples available. Luminal B type confirmed by immunohistochemistry or, preferably, genomic profiling using Next-Generation Sequencingwith ER ≥120% and Ki67 ≥20% and not HER2 amplified, or, if aged 40 or younger and/or verified lymph node metastases, luminal A type, defined as ER and PR positive ≥20% and the proliferation marker Ki 67 <20% and not HER2 amplified. Any luminal B, Luminal A with verified lymph node metastases and/or aged 40 or younger
- Age 18 years or older. Elderly patients in condition adequate for planned therapy
- Primary breast cancer >20mm in diameter and/or verified regional lymph node metastases
- Adequate bone marrow, renal, hepatic and cardiac functions and no other uncontrolled medical or psychiatric disorders
- LVEF >55%
- ECOG performance status 0-1
- Primary breast cancer as defined in p. 5 plus at most 2 morphologically characterized well-defined distant metastases accessible for stereotactic radiotherapy, provided that this treatment is available
Exclusion Criteria:
- Distant metastases, including node metastases in the contralateral thoracic region or in the mediastinum
- Other malignancy diagnosed within the last five years, except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix
- Patients in child-bearing age without adequate contraception
- Pregnancy or lactation
- Uncontrolled hypertension, heart, liver, kidney related or other medical or psychiatric disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A: Weekly Paclitaxel
Patients receive weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for a 12-week period.
Thereafter, treatment is switched to endocrine treatment in combination with palbociclib.
Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during the second 12-week period
|
Any brand of paclitaxel may be used, excluding nab-paclitaxel
|
Experimental: B: Tamoxifen + Palbociclib
Pre- or perimenopausal women and all men are treated with tamoxifen together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period.
Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
|
Any brand of tamoxifen may be used
Other Names:
|
Experimental: B: Aromatase Inhibitor + Palbociclib
Postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period.
Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
|
Any brand of letrozole, anastrozole or exemestane may be used
Other Names:
|
Experimental: B: Goserelin + Aromatase Inhibitor + Palbociclib
Pre- or perimenopausal women may be treated with goserelin and an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period.
Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
|
Any brand of letrozole, anastrozole or exemestane may be used
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiological Objective Response Rate after Completion of the First 12-week Period of Primary Medical Treatment
Time Frame: Start of treatment until 12 weeks of treatment
|
Radiological response by use of mammography and ultrasound, alternatively MRI of the breast, if mammography/ultrasound does not allow for objective measurements of the primary tumor.
Clinical measurements using calliper, if the tumor is palpable and tumor size cannot be estimated by radiological methods
|
Start of treatment until 12 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Objective Response Rate
Time Frame: From the date of surgery up to 4 weeks after surgery
|
Presence/abscense of residual tumor in mm, fibrosis and other signs of response by histology
|
From the date of surgery up to 4 weeks after surgery
|
Sequencing of Chemotherapy versus Endocrine Treatment plus Palbociclib in relation to Radiological Objective Response Rate after Completion of the 24-week Period of Primary Medical Treatment
Time Frame: From start of treatment until termination of the preoperative treatment after 24 weeks
|
Radiological response by use of mammography and ultrasound, alternatively MRI of the breast, if mammography/ultrasound does not allow for objective measurements of the primary tumor.
Clinical measurements using calliper, if the tumor is palpable and tumor size cannot be estimated by radiological methods
|
From start of treatment until termination of the preoperative treatment after 24 weeks
|
Disease-Free Survival
Time Frame: From date of surgery until 10 years past surgery
|
Disease-free survival includes all events related to breast cancer, and death from any cause during the follow-up period
|
From date of surgery until 10 years past surgery
|
Breast Cancer-Specific Survival
Time Frame: From date of surgery until 10 years past surgery
|
Breast cancer-specific survival includes all events related to breast cancer and death caused by breast cancer during the follow-up period
|
From date of surgery until 10 years past surgery
|
Overall Survival
Time Frame: From date of surgery until 10 years past surgery
|
Overall survival relates to death from any cause during the follow-up period
|
From date of surgery until 10 years past surgery
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: From start of treatment until 28 days after termination of 24 weeks of treatment. Delayed toxicity is reported until 60 months follow-up
|
Safety will be assessed using NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE) for reporting laboratory and non-laboratory toxicities
|
From start of treatment until 28 days after termination of 24 weeks of treatment. Delayed toxicity is reported until 60 months follow-up
|
Health-Related Quality of Life
Time Frame: From start of study treatment until termination after 24 weeks, and then annually during 5 years of postoperative follow-up period
|
From start of study treatment until termination after 24 weeks, and then annually during 5 years of postoperative follow-up period
|
|
Frequency of Breast-Conserving Surgery
Time Frame: At surgery after neoadjuvant therapy
|
Refers to the rate of patients who are operated with breast-conserving surgery compared with mastectomy
|
At surgery after neoadjuvant therapy
|
Characteristics of the Genome of Previously Untreated Tumors Before and After Exposition to Treatment
Time Frame: Before start and during treatment, at surgery, and then annually during the 60 months of postoperative follow-up period
|
New Generation Sequencing (NGS) is performed on biopsies from the tumors with the aim to classify the tumors according to PAM50.
Repeated analyses of tumor tissue during the treatment process will be performed to identify heterogeneity and mutations which might be responsible for resistance to study treatment.
Blood samples are collected to identify tumor DNA sequences which might predict recurrence during the follow-up period.
Tissue and blood samples are also analyzed in case of recurrence.
The results are descriptive and expressed as clustering.
Units of measure are lacking
|
Before start and during treatment, at surgery, and then annually during the 60 months of postoperative follow-up period
|
Changes of the Proteome of Previously Untreated Tumors Before and After Exposition to Treatment
Time Frame: Before start, during treatment and at surgery
|
Proteome analyses with the intention to identify tumor-specific pathways are performed on repeated biopsies from the tumors.
The results are descriptive, defined units of measure are lacking
|
Before start, during treatment and at surgery
|
Quantification of Hormone Receptors Before and After Treatment
Time Frame: Before start, during treatment and at surgery
|
Immunohistochemistry on core biopsies before start, after 10 weeks of treatment, and tumor samples from the surgical specimen.
Presence of estrogen receptor (ER) and progesterone receptor (PR), described as percentage in relation to the total count of tumor cells
|
Before start, during treatment and at surgery
|
Quantification of Proliferation Before and After Treatment
Time Frame: Before start, during treatment and at surgery
|
Immunohistochemistry on core biopsies before start, after 10 weeks of treatment, and tumor samples from the surgical specimen.
Presence of cells indicating proliferation by use of Ki67, described as percentage in relation to the total count of tumor cells
|
Before start, during treatment and at surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Thomas Hatschek, Assoc Prof, Breast-sarcoma Unit, Dept. of Oncology, Karolinska University Hospital
- Study Director: Jonas Bergh, Professor, Dept. of Oncology-Pathology, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Phytogenic
- Protein Kinase Inhibitors
- Hormone Antagonists
- Bone Density Conservation Agents
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Paclitaxel
- Letrozole
- Palbociclib
- Goserelin
- Tamoxifen
- Anastrozole
- Exemestane
- Aromatase Inhibitors
Other Study ID Numbers
- PREDIX LumB
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early-Stage Breast Carcinoma
-
Jonsson Comprehensive Cancer CenterRecruitingEarly Stage Breast CarcinomaUnited States
-
Cyrcadia HealthStanford University; Ohio State University; SalesforceUnknown
-
Cliniques universitaires Saint-Luc- Université...CompletedObservational Trial on the Impact of Hypnose Used as a Sedation in Oncology Surgery in Breast CancerEarly Stage Breast CarcinomaBelgium
-
Breast Cancer Trials, Australia and New ZealandETOP IBCSG Partners Foundation; Breast International GroupRecruitingEarly Stage Breast CarcinomaTaiwan, Australia, Spain, New Zealand, Ireland, Italy, Argentina, Switzerland, Chile
-
University Hospital Schleswig-HolsteinUniversity of LuebeckActive, not recruitingEarly-Stage Breast CarcinomaGermany
-
European Institute of OncologyActive, not recruitingEarly Stage Breast CarcinomaItaly, Chile, Spain, Switzerland
-
Kliniken Essen-MitteGerman Breast GroupCompletedEarly-Stage Breast CarcinomaGermany, Switzerland
-
University College, LondonUnknownEarly-Stage Breast CarcinomaUnited Kingdom
-
Centre Henri BecquerelUnknownTolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer (EPIC)Early Stage Breast CarcinomaFrance
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Shengjing HospitalRecruiting
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium